iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Acquired by Wellington Management Group LLP

Wellington Management Group LLP grew its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 20.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 105,769 shares of the company’s stock after acquiring an additional 18,255 shares during the quarter. Wellington Management Group LLP’s holdings in iTeos Therapeutics were worth $1,080,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. nVerses Capital LLC increased its stake in iTeos Therapeutics by 212.5% during the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock valued at $26,000 after purchasing an additional 1,700 shares in the last quarter. Point72 DIFC Ltd acquired a new position in shares of iTeos Therapeutics in the 3rd quarter valued at $31,000. China Universal Asset Management Co. Ltd. raised its stake in iTeos Therapeutics by 60.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock worth $72,000 after acquiring an additional 2,646 shares during the last quarter. Quest Partners LLC lifted its position in iTeos Therapeutics by 914.7% during the 3rd quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock worth $113,000 after acquiring an additional 9,934 shares during the period. Finally, US Bancorp DE grew its stake in iTeos Therapeutics by 206.0% during the 3rd quarter. US Bancorp DE now owns 12,076 shares of the company’s stock valued at $123,000 after purchasing an additional 8,129 shares during the last quarter. 97.16% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ITOS. Wells Fargo & Company reduced their price objective on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a research note on Thursday. Wedbush reissued an “outperform” rating and set a $25.00 price target on shares of iTeos Therapeutics in a research report on Thursday, December 12th. Finally, HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of iTeos Therapeutics in a research note on Friday, December 13th.

Insider Buying and Selling

In other iTeos Therapeutics news, CFO Matthew Gall purchased 5,000 shares of iTeos Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The stock was bought at an average price of $7.73 per share, with a total value of $38,650.00. Following the acquisition, the chief financial officer now owns 65,429 shares of the company’s stock, valued at $505,766.17. This trade represents a 8.27 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 12.50% of the stock is currently owned by insiders.

iTeos Therapeutics Stock Down 0.6 %

Shares of ITOS stock opened at $7.22 on Friday. iTeos Therapeutics, Inc. has a 52-week low of $7.12 and a 52-week high of $18.75. The stock has a market cap of $263.78 million, a PE ratio of -2.29 and a beta of 1.37. The business has a 50-day simple moving average of $8.59 and a 200-day simple moving average of $12.71.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, topping the consensus estimate of ($1.18) by $0.13. Sell-side analysts anticipate that iTeos Therapeutics, Inc. will post -3.46 earnings per share for the current fiscal year.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.